|
MechanismCav2.1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.SE |
First Approval Date28 Mar 1998 |
|
MechanismHMG-CoA reductase inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Gador SA
0 Patents (Medical) associated with Gador SA
100 Deals associated with Gador SA
100 Translational Medicine associated with Gador SA